相关实验视频

Updated: Jul 28, 2025

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

托塞拉尼布酸盐 (Palladia) 通过在小鼠中保持小岛功能来逆转1型糖尿病

Kazuhisa Kishi¹, Tomohiro Yonezawa², Noriyuki Kaji³

¹Department of Veterinary Pharmacology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, Japan.

The Journal of veterinary medical science

|May 31, 2023

概括

托塞拉尼布 (TOC) 是一种氨酸激酶抑制剂,通过保护β细胞,在小鼠中逆转了1型糖尿病 (T1D). 这表明,通过保持小岛功能来治疗T1D的潜在兽医应用.

科学领域:

免疫学免疫学免疫学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

1型糖尿病 (T1D) 是一种自身免疫性疾病,其特征是β细胞的破坏.
目前的T1D治疗重点是胰岛素替代,但针对β细胞保护的新型免疫疗法正在出现.
托塞拉尼布 (TOC) 是一种受体类型的氨酸激酶 (RTK) 抑制剂,在兽医中使用.

研究的目的:

调查托塞拉尼布 (TOC) 作为1型糖尿病 (T1D) 免疫治疗干预的潜力.
探索血小板衍生生长因子受体 (PDGFR) 抑制在T1D逆转中的作用.

主要方法:

链毒素诱导的T1D小鼠模型.
托塞拉尼布 (TOC) 的使用.
胰腺小岛的组织病理学检查.
评估血糖控制和血清胰岛素水平.
对PDGFR抑制的研究.

主要成果:

TOC逆转了链毒素诱导的T1D,改善了肌肉和骨代谢异常.
TOC抑制了β细胞的枯竭,并恢复了血清胰岛素水平.
在慢性T1D模型中,TOC的有效性降低了,并且具有显著的β细胞损失.
抑制PDGFR,这是TOC的标,也逆转了小鼠中确定的T1D.
通过抑制RTK,TOC保留了小岛的功能,这表明T1D治疗的新机制.

结论:

托塞拉尼布 (TOC) 通过RTK抑制维护β细胞功能,证明了对1型糖尿病 (T1D) 的治疗潜力.
抑制PDGFR是TOC在T1D中发挥有益作用的关键机制.
这些发现突出了TOC以前未知的药理特性,表明其在兽医T1D治疗中的潜在应用.

关键词:

抗癌药物是一种抗癌药物.在糖尿病中,糖尿病是血糖类的.药物重新定位药物重新定位铁氨酸激酶酶的使用方法

更多相关视频

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...